Difference between revisions of "Team:NTHU Formosa/Description"

 
(31 intermediate revisions by 3 users not shown)
Line 10: Line 10:
 
   <link rel="stylesheet" type="text/css" href="https://2018.igem.org/wiki/index.php?title=Template:NTHU_Formosa/initial&action=raw&ctype=text/css">
 
   <link rel="stylesheet" type="text/css" href="https://2018.igem.org/wiki/index.php?title=Template:NTHU_Formosa/initial&action=raw&ctype=text/css">
 
   <link rel="stylesheet" type="text/css" href="https://2018.igem.org/wiki/index.php?title=Template:NTHU_Formosa/wordcss0&action=raw&ctype=text/css">
 
   <link rel="stylesheet" type="text/css" href="https://2018.igem.org/wiki/index.php?title=Template:NTHU_Formosa/wordcss0&action=raw&ctype=text/css">
−
<link rel="stylesheet" type="text/css" href="https://2018.igem.org/wiki/index.php?title=Template:NTHU_Formosa/wordcss&action=raw&ctype=text/css">
+
  <link rel="stylesheet" type="text/css" href="https://2018.igem.org/wiki/index.php?title=Template:NTHU_Formosa/wordcss&action=raw&ctype=text/css">
 
   <style>
 
   <style>
 
     /* unvisited link */
 
     /* unvisited link */
  
 
     a {
 
     a {
−
       color: white;
+
       color: #0645AD;
 
     }
 
     }
  
Line 21: Line 21:
  
 
     a:visited {
 
     a:visited {
−
       color: white;
+
       color: green;
 
     }
 
     }
  
Line 30: Line 30:
 
       cursor: pointer;
 
       cursor: pointer;
 
     }
 
     }
 +
 +
  
 
     /* selected link */
 
     /* selected link */
  
 
     a:active {
 
     a:active {
−
       color: white;
+
       color: blue;
 
     }
 
     }
−
 
−
 
−
 
 
   </style>
 
   </style>
 
</head>
 
</head>
  
 
<!-- Main Section -->
 
<!-- Main Section -->
−
  <div class="w3-container w3-padding-24 w3-center">
+
<div class="w3-container w3-padding-24 w3-center">
−
    <div class="w3-content"><br><br><br>
+
  <div class="w3-content">
−
      <h2 class="w3-wide" style="font-size:60px;">Introduction</h2><br>
+
    <br>
 +
    <br>
 +
    <br>
 +
    <h2 class="w3-center" style="font-size:60px; font-family:Quicksand;"><b>BioWatcher</b></h2>
 +
    <p class="w3-center" style="font-size:37px; font-family:Quicksand;">
 +
      <b>Watch your health</b></p>
 +
    <br>
  
  
  
−
<br> <br>  
+
 
−
     <video width="800" height="500" src="https://static.igem.org/mediawiki/2018/1/12/T--NTHU_Formosa--Demo_Vedio_.mp4" controls></video><br> <br>  
+
    <br>
 +
    <br>
 +
     <video width="800" height="500" src="https://static.igem.org/mediawiki/2018/1/12/T--NTHU_Formosa--Demo_Vedio_.mp4" controls></video>
 +
    <br>
 +
    <br>
 
     <p class="w3-justify">
 
     <p class="w3-justify">
  
−
       <br> 　People around the world are growing awareness of their health condition. To monitor the health condition, a wide range of biomarkers-- special substances in the bloodstream representing the physiological and pathological states-- has been used
+
       <br> 　People around the world are growing awareness of their health condition. To monitor the health condition, a wide range of <a href="https://2018.igem.org/Team:NTHU_Formosa/Biomarker"><b>biomarkers</b></a>, which are special substances in the bloodstream representing the physiological and pathological states, has been used in
−
       in clinical diagnoses. Blood test is one of the most common ways of detecting biomarkers but it suffers from several inevitable drawbacks such as invasiveness, time-consuming procedure, demand for medical staff service, non-real-time tracking and
+
       clinical diagnosis. Blood test is one of the most common ways of detecting biomarkers but it suffers from several inevitable drawbacks such as invasiveness, time-consuming procedure, demand for medical staff service, non-real-time tracking and so
−
       so on. These disadvantages may discourage people from the periodic medical checkup. Indeed, according to a survey (of 1862 samples) pulled by our team, nearly half of the participants took blood test less than once a five-year frequency, which is
+
       on. These disadvantages may discourage people from the periodic medical checkup. Indeed, according to a survey (of 1862 samples) pulled by our team, nearly half of the participants took blood test less than once a five-year frequency, which is impractical
−
       impractical for early detection and early treatment of diseases.</p>
+
       for early detection and early treatment of diseases.</p>
 
     <br>
 
     <br>
 
     <br>
 
     <br>
 
     <br>
 
     <br>
 
     <br>
 
     <br>
−
     <p class="w3-center"><b>Blood test frequency survey</b></p>
+
     <h2 class="w3-justify" style="font-size:20px;  padding-left: 340px"><b>Blood test frequency survey</b></h2>
−
     <img class="w3-center" src="https://static.igem.org/mediawiki/2018/e/e1/T--NTHU_Formosa--introdction_survey.png" align=center style="width:60%;margin:0px 20px 0px 150px;" ;>
+
 
 +
     <img class="w3-round-large" src="https://static.igem.org/mediawiki/2018/3/3c/T--NTHU_Formosa--newbar.png" style="margin-left:auto;margin-right:auto;width:65%;" ;>
 +
 
  
 
     <div class="w3-container w3-padding-24 w3-center">
 
     <div class="w3-container w3-padding-24 w3-center">
 
       <div class="w3-content">
 
       <div class="w3-content">
 
         <p class="w3-justify">
 
         <p class="w3-justify">
−
           <br> 　To get rid of limits such as invasiveness and non-real-time tracking, our team proposed <b><i>BioWatcher</i></b>, engineered reporter cells that enable detection and autonomous report of soluble biomarkers in the bloodstream. The sensing parts
+
           <br> 　To get rid of limits such as invasiveness and non-real-time tracking, our team proposed <b><i>BioWatcher</i></b>, engineered reporter cells that enable detection and autonomous report of soluble <a href="https://2018.igem.org/Team:NTHU_Formosa/Biomarker"><b>biomarkers</b> </a>          in the bloodstream. The sensing parts of the reporter cells are powered by <a href="https://2018.igem.org/Team:NTHU_Formosa/Nanobody"> <b>nanobodies</b> </a>, the single-domain antibody that can be engineered to detect different biomarkers. Binding
−
          of the reporter cells are powered by nanobodies, the single-domain antibody that can be engineered to detect different biomarkers. Binding of biomarkers on nanobodies triggers our synthetic gene circuits and, in turn, induces autonomous bioluminescence
+
          of biomarkers on nanobodies triggers our synthetic gene circuits and, in turn, induces autonomous <a href="https://2018.igem.org/Team:NTHU_Formosa/Bioluminescence"><b>bioluminescence </b></a> system as the readout for devices to detect. This
−
          system as the readout for devices to detect. This kind of autonomous reporting system can have great varieties of applications by installation on wearable devices, watches for example. With the required software, the wearable devices could track
+
          kind of autonomous reporting system can have great varieties of applications by installation on wearable devices, watches for example. With the required software, the wearable devices could track the level of risk factors by measuring the bioluminescence
−
          the level of risk factors by measuring the bioluminescence intensity and record the data as numbers and graphs. It will send an alert to users once the level of the risk factors is too high. Meanwhile, there will be suggestions for nearby hospitals
+
          radiance and record the data as numbers and graphs. It will send an alert to users once the level of the risk factors is too high. Meanwhile, there will be suggestions for nearby hospitals according to the users’ location. The system will also
−
          according to the users’ location. The system will also upload and attribute the data to public health analysis under the users’ consent.</p>
+
          upload and attribute the data to public health analysis under the users’ consent. With BioWatcher, we hope to watch everyone's health daily and prevent death caused by late treatment. Moreover, this system will be even more useful and required
 +
          for patients with fear of cancer recurrence even though BioWatcher is not limited to detecting cancers. We believe BioWatcher has the potential to be a revolutionary diagnostic approach! </p>
 
         <br>
 
         <br>
 
         <br>
 
         <br>

Latest revision as of 19:47, 17 October 2018




BioWatcher

Watch your health







　People around the world are growing awareness of their health condition. To monitor the health condition, a wide range of biomarkers, which are special substances in the bloodstream representing the physiological and pathological states, has been used in clinical diagnosis. Blood test is one of the most common ways of detecting biomarkers but it suffers from several inevitable drawbacks such as invasiveness, time-consuming procedure, demand for medical staff service, non-real-time tracking and so on. These disadvantages may discourage people from the periodic medical checkup. Indeed, according to a survey (of 1862 samples) pulled by our team, nearly half of the participants took blood test less than once a five-year frequency, which is impractical for early detection and early treatment of diseases.





Blood test frequency survey


　To get rid of limits such as invasiveness and non-real-time tracking, our team proposed BioWatcher, engineered reporter cells that enable detection and autonomous report of soluble biomarkers in the bloodstream. The sensing parts of the reporter cells are powered by nanobodies , the single-domain antibody that can be engineered to detect different biomarkers. Binding of biomarkers on nanobodies triggers our synthetic gene circuits and, in turn, induces autonomous bioluminescence system as the readout for devices to detect. This kind of autonomous reporting system can have great varieties of applications by installation on wearable devices, watches for example. With the required software, the wearable devices could track the level of risk factors by measuring the bioluminescence radiance and record the data as numbers and graphs. It will send an alert to users once the level of the risk factors is too high. Meanwhile, there will be suggestions for nearby hospitals according to the users’ location. The system will also upload and attribute the data to public health analysis under the users’ consent. With BioWatcher, we hope to watch everyone's health daily and prevent death caused by late treatment. Moreover, this system will be even more useful and required for patients with fear of cancer recurrence even though BioWatcher is not limited to detecting cancers. We believe BioWatcher has the potential to be a revolutionary diagnostic approach!